BACKGROUND: Idiopathic pulmonary fibrosis(IPF) continues to be a fatal disease despite the use of antifibrotic therapy. There is limited data on the prognostic importance of parameters predicting mortality. We aimed to identify independent mortality predictors in antifibrotic-treated IPF patients. METHODS: With ethics committee approval, IPF patients receiving consecutively antifibrotic treatment between 1 January 2013-01.01.2023 at Izmir Dr Suat Seren Chest Disease and Surgery Training and Research Hospital were retrospectively screened. The clinical-demographic-radiologic data were recorded. Cox regression and Kaplan-Meier analyses explored associations with mortality; receiver-operating-characteristic (ROC) curves defined optimal cutoffs. RESULTS: = 0.048). CONCLUSION: Patients with symptom progression, mMRC >2, presence of honeycombing on radiological imaging, FVC ≤71%, and CPI >49.2 have a higher risk of mortality and should be referred for pulmonary rehabilitation and lung transplantation evaluation at an early stage.
No takes yet. Share an insight, caveat, or question.
Aras et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: